Skip to main content
Clinical Trials/NCT01782677
NCT01782677
Completed
Not Applicable

Bilateral Surgical Resection of Carotid Bodies in Patients With Systolic Heart Failure

Noblewell1 site in 1 country5 target enrollmentDecember 2012

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Systolic Heart Failure
Sponsor
Noblewell
Enrollment
5
Locations
1
Primary Endpoint
Muscle sympathetic nerve activity
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

The primary aim of the study is to determine safety, tolerability and feasibility of bilateral carotid body resection in patients with systolic heart failure and peripheral chemoreceptor hypersensitivity. The secondary aim is to assess potential efficacy of bilateral carotid body resection.

Registry
clinicaltrials.gov
Start Date
December 2012
End Date
December 2013
Last Updated
9 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Noblewell
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • History of heart failure class II-III according to NYHA within at least 6 months prior to inclusion
  • Stable clinical state within at least 4 weeks prior to inclusion
  • Subject \>= 18 years old
  • Left ventricular ejection fraction ≤ 45% evaluated by transthoracic echocardiography (Simpson's method)
  • Carotid body present in computer cervical angiotomography
  • History of exacerbated peripheral chemoreceptor sensitivity determined as \>0.6L/min/%SpO2
  • Able and willing to give written informed consent

Exclusion Criteria

  • Unstable angina pectoris, coronary attack, coronary revascularization, exacerbation of heart-failure requiring hospitalization, clinically significant infection, surgery under general anesthesia within 3 months prior to inclusion
  • History of stroke, transient ischemic attack (TIA), or clinically significant chronic neurological disorder
  • History of heart transplant
  • Pregnancy or anticipation of pregnancy
  • Hemodialysis or peritoneal dialysis patients
  • Obstructive carotid atherosclerotic disease with \>50% stenosis
  • COPD stage III and IV according to GOLD 2007
  • Unable to perform the spiroergometric assessment
  • Any significant anomaly in additional investigation which may increase the risk of study procedure

Outcomes

Primary Outcomes

Muscle sympathetic nerve activity

Time Frame: 4 weeks

Change from baseline in muscle sympathetic nerve activity at 4 weeks.

Peripheral chemosensitivity

Time Frame: 4 weeks

Change from baseline in peripheral chemosensitivity measured as ventilatory response to hypoxia using transient inhalation of nitrogen at 4 weeks.

Secondary Outcomes

  • Heart function and morphology(8 weeks)
  • Sleep pattern in PSG(8 weeks)
  • Arrhythmia burden(8 weeks)
  • Exercise tolerance(8 weeks)
  • Quality of life(8 weeks)
  • Serum concentration of NT-proBNP(8 weeks)
  • Barosensitivity(8 weeks)
  • Peripheral chemosensitivity(8 weeks)
  • Muscle sympathetic nerve activity(8 weeks)

Study Sites (1)

Loading locations...

Similar Trials